Skip to main navigation Skip to search Skip to main content

Phenotypic spectrum in individuals with pathogenic GABRG2 loss- and gain-of-function variants

  • Alessandra Rossi
  • , Susan X.N. Lin
  • , Nathan L. Absalom
  • , Sebastian Ortiz-De la Rosa
  • , Vivian W.Y. Liao
  • , Nazanin A. Mohammadi
  • , Sindhu Viswanathan
  • , Tommy Stödberg
  • , Alberto Danieli
  • , Paolo Bonanni
  • , Alec Aeby
  • , Alessandro Orsini
  • , Alice Bonuccelli
  • , Andrea Rüegger
  • , Beatriz G. Giraldez
  • , Bertrand Isidor
  • , Burkhard Stüve
  • , Carla Marini
  • , Elisabetta Cesaroni
  • , Christina D. Fenger
  • Christophe Philippe, Colombine Meunier, Damien Lederer, Stéphanie Moortgat, Egidio Spinelli, Elisa Fallica, Fiona Zeiner, Matthias Bauman, Laura Licchetta, Francesca Bisulli, Francesca F. Operto, Ira Benkel-Herrenbrueck, Kathleen M. Gorman, Katrine M. Johannesen, Konrad Platzer, Franziska Schnabel, Lieven Lagae, Mirjam Laufs, Riina Zordania, Stephen Malone, Tullio Messana, Wendy Werckx, Charlotta Jonsson, Zaid Afawi, Thomas Foiadelli, Yosra Halleb, Radka Stoeva, Mélanie Jennesson-Lyver, Gaetan Lesca, Renzo Guerrini, Samuel F. Berkovic, Ingrid E. Scheffer, Mary Chebib, Elena Gardella, Rikke S. Møller, Guido Rubboli, Philip K. Ahring
  • Danish Epilepsy Centre, Dianalund
  • University of Pavia
  • The University of Sydney
  • University of Southern Denmark
  • University of Melbourne
  • Karolinska Institutet
  • IRCCS E. Medea Scientific Institute
  • Queen Fabiola Children's University Hospital
  • Pisa University Hospital
  • University of Zurich
  • Hospital Universitario and IIS Fundación Jiménez Díaz and CIBERER
  • CHU Nantes
  • Children's Hospital Siegen
  • Pediatric Hospital G. Salesi
  • Amplexa Genetics
  • Université de Bourgogne
  • Centre Hospitalier Régional Metz-Thionville
  • Institut de Pathologie et de Génétique
  • Western University
  • Azienda Ospedaliero Universitaria of Ferrara
  • Innsbruck Medical University
  • IRCCS Istituto delle Scienze Neurologiche di Bologna
  • University of Bologna
  • Magna Græcia University
  • Heinrich Heine University Düsseldorf
  • Children’s Health Ireland
  • University College Dublin
  • University of Copenhagen
  • Leipzig University
  • KU Leuven
  • University Hospital Schleswig-Holstein
  • Tartu University Hospital
  • Children’s Health Queensland
  • University of Queensland
  • Jessa Hospital
  • Linköping University
  • Ben-Gurion University of the Negev
  • Erasmus University Rotterdam
  • Centre Hospitalier Le Mans
  • CHU de Reims
  • Universite Claude Bernard Lyon 1
  • Institut national de la santé et de la recherche médicale
  • Meyer Children's Hospital IRCCS
  • University of Florence

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
2 Downloads (Pure)

Abstract

Background and ObjectivesVariants in the GABRG2 gene encoding the γ2 subunit of the γ-aminobutyric acid type A (GABAA) receptor are associated with a spectrum of epilepsy phenotypes. These range from simple febrile seizures to more severe conditions, including developmental and epileptic encephalopathies (DEEs). Despite previous analyses suggesting that pathogenic variants may lead to loss-of-function (LoF) receptors, a correlation between functional analysis and clinical phenotypic diversity remains elusive. We, therefore, aimed to determine why variants in the GABRG2 gene can lead to highly diverse phenotypes.MethodsWe assembled a cohort of unreported probands carrying presumed pathogenic GABRG2 variants. Electroclinical information was systematically collected, and electrophysiologic measurements were conducted for missense variants to explore potential alterations in receptor function.ResultsWe examined 44 individuals with 35 GABRG2 variants (18 null and 17 missense). Functional assessments of the missense variants revealed that 9 caused LoF and 3 caused gain-of-function (GoF). The remaining 5 did not alter receptor function and are likely not pathogenic. Based on functional analysis and electroclinical data, 37 affected individuals were categorized into 3 groups: null LoF, missense LoF, and GoF variants. Among 19 individuals with null variants, epilepsy was diagnosed in 13, with a median onset of 14 months. The remaining 6 of 19 only had febrile seizures. Developmental delay/intellectual disability (DD/ID) was observed in 1 of 19 and psychiatric features in 4 of 18. By contrast, all 12 individuals with missense LoF variants suffered from epilepsy with a median onset of 15 months. Most common epilepsy diagnoses were febrile seizures plus in 4 of 12 and DEE in 4 of 12. DD/ID affected 9 of 12, and psychiatric features were diagnosed in 8 of 12. Statistical comparisons revealed that null variants were associated with a milder phenotype than missense LoF variants. Finally, 5 of 6 individuals with GoF variants had DEE characterized by early infancy onset at 2 months and severe/profound DD/ID. The sixth individual exhibited mild DD/ID and hypotonia without seizures.DiscussionOur findings indicate that the severity of disease associated with pathogenic GABRG2 variants depends on the functional consequences of the variants. Null variants are associated with a mild phenotype and missense LoF variants with an intermediate phenotype while GoF variants can lead to severe phenotypes.

Original languageEnglish
Article numbere213644
Number of pages16
JournalNeurology
Volume105
Issue number2
DOIs
Publication statusPublished - 26 Jun 2025

Bibliographical note

Publisher Copyright:
© 2025 American Academy of Neurology.

Fingerprint

Dive into the research topics of 'Phenotypic spectrum in individuals with pathogenic GABRG2 loss- and gain-of-function variants'. Together they form a unique fingerprint.

Cite this